OSLO, Norway, Dec. 20, 2017 /PRNewswire/ --
An Extraordinary General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 20 December 2017 in Oslo, Norway (the "EGM").
All proposals were resolved by the EGM as presented in the notice convening the EGM.
The complete minutes of the EGM are attached to this release and is also available on www.nordinanovector.com.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information is subject to duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact:
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Nordic Nanovector